Document:

<PAGE>
                                                                    Exhibit 10.8
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------

                               LICENSE AGREEMENT

                                    BETWEEN

                   UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION

                                      AND

                         CONTROL DELIVERY SYSTEMS, INC.

                               September 9, 1997

--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
<PAGE>

                               TABLE OF CONTENTS
<TABLE>
<CAPTION>

<S>                                                                       <C>
ARTICLE 1 - DEFINITIONS.................................................... 1

ARTICLE 2 - GRANT.......................................................... 3

ARTICLE 3 - CONFIDENTIALITY................................................ 3

ARTICLE 4 - REPRESENTATIONS AND WARRANTIES................................. 6

ARTICLE 5 - ROYALTIES...................................................... 7

ARTICLE 6 - REPORTS AND RECORDS............................................ 9

ARTICLE 7 - PATENT PROSECUTION AND ENFORCEMENT.............................10

ARTICLE 8 - TERMINATION....................................................12

ARTICLE 9 - INDEMNIFICATION................................................13

ARTICLE 10 - ASSIGNMENT....................................................13

ARTICLE 11 - AGENCY........................................................14

ARTICLE 12 - PAYMENTS, NOTICES AND COMMUNICATIONS..........................14

ARTICLE 13 - MISCELLANEOUS PROVISIONS......................................14
</TABLE>
<PAGE>

                               LICENSE AGREEMENT

     This AGREEMENT, effective as of this 9th day of September, 1997 ("EFFECTIVE
DATE"), by and between the UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, a
corporation duly organized and existing under the laws of the Commonwealth of
Kentucky and having a principal office at 11 Administration Building, Lexington,
Kentucky (hereinafter referred to as "UKRF"), and CONTROL DELIVERY SYSTEMS,
INC., a Delaware corporation having its principal office at 86 Rosedale Road,
Watertown, Massachusetts  02172 ("LICENSEE").

     WHEREAS, UKRF is the duly authorized agent of the University of Kentucky
for purposes of managing research support and intellectual property rights;

     WHEREAS, LICENSEE has sponsored certain research (the "Research") at the
University of Kentucky which resulted in the patent application identified on
Exhibit A hereto (the "Patent Application");

     WHEREAS, UKRF desires to have certain proprietary information conceived
and/or made in the course of performing the Research, including the Patent
Application, and any resulting patent rights, used in the public interest and is
willing to grant a license thereto on the terms set forth below; and

     WHEREAS, LICENSEE desires to obtain a license for such proprietary
information and any resulting patent rights upon the terms and conditions
hereinafter set forth.

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
contained herein, the parties agree as follows:

                            ARTICLE 1 - DEFINITIONS

     As used herein, the following terms shall have the following meanings:

     1.1  "AFFILIATE" shall mean a corporation or other business entity
controlled by, controlling or under common control with, a party hereto.  For
this purpose, control of a corporation or other business entity shall mean
direct or indirect beneficial ownership of twenty-five percent (25%) or more of
the voting interest in, or a twenty-five percent (25%) or greater interest in
the equity of, such corporation or other business entity.

     1.2  "FIRST COMMERCIAL SALE" shall mean the initial transfer by LICENSEE,
its AFFILIATE or sublicensee, to an unrelated third party of LICENSED PRODUCTS
subject to royalties hereunder for commercial use and not for research,
development or testing purposes.
<PAGE>

     1.3  "LICENSED PRODUCTS" shall mean any product the manufacture or sale of
which, in the absence of a license, will infringe a Valid Claim in a pending
application or an issued patent in PATENT RIGHTS; or any product which makes use
of all or a portion of the TECHNOLOGY.

     1.4  "NET ROYALTIES" shall mean (a) the royalties based on NET SALES
collected by LICENSEE from its sublicensees for LICENSED PRODUCTS subject to
royalties hereunder, less the amount of any tax required to be withheld by a
government or governmental agency, and (b) any other fees received by LICENSEE
from its sublicensees in respect of the sale, or the right to sell LICENSED
PRODUCTS.  NET ROYALTIES shall not include amounts paid by a sublicensee to
LICENSEE (i) as reimbursement of expenses, (ii) that are payable in respect of
research or development or (iii) to fund research and development, or (iv) in
respect of the sale of other transfer of LICENSEE'S entire business or of that
part of LICENSEE'S business to which the license granted hereby relates.

     1.5  "NET SALES" shall mean the gross revenues collected from unrelated
third party customers by LICENSEE's sublicensees for LICENSED PRODUCTS subject
to royalties hereunder, less the amount actually allowed to such customers for
(a) any credits and allowances and adjustments granted to such customers on
account of the rejection or return of such LICENSED PRODUCTS previously sold,
(b) trade and cash discounts, rebates and distributor fees (but not sales
commissions) paid to unrelated third parties, (c) transportation, insurance and
handling charges, (d) sales, excise, turnover and similar taxes and any duties
and other governmental charges imposed upon the production, importation, use or
sale of such LICENSED PRODUCTS, (e) uncollectible debt and (f) royalties, fees
or cost of drug acquisition paid, directly or pursuant to a license, to holders
of patents for drugs used in connection with the LICENSED PRODUCTS, which shall
not exceed the average wholesale price for such drugs.  LICENSED PRODUCTS shall
be considered "sold" when billed out or invoiced to a third party.  In the event
that the LICENSED PRODUCT is sold in combination with one or more ingredients
which are not LICENSED PRODUCTS (e.g., a product combining more than one active
ingredient), Net Sales for computing royalties hereunder shall be determined by
multiplying Net Sales, as defined above, of such combination product (e.g., more
than one active ingredient) by a fraction, the numerator of which shall be
whichever is the higher of (1) the current standard list price for quantities
equal to the quantity listed or (2) the cost of manufacture, including direct
labor, materials consumed, and overhead plus one hundred percent (100%) thereof,
computed in accordance with generally accepted accounting practices
(consistently applied) of the LICENSED PRODUCT content thereof, and the
denominator shall be the total price or cost, calculated on the same basis as
the numerator, of all ingredients (including the LICENSED PRODUCT content as in
the numerator) contained in such combination product.

     1.6  "PATENT RIGHTS" shall mean (a) the United States and foreign patents
or pending United States and foreign patent applications set forth in Exhibit A
hereto and any other United States or foreign applications subsequently filed by
UKRF which arise out of the

                                       2
<PAGE>

inventions described in Exhibit A or which are based on the TECHNOLOGY; (b) any
additions, continuations, continuations-in-art, divisions, reissues or
extensions based thereon; (c) any United States or foreign patent obtained from
any of said United States or foreign patent applications; and (d) any other
proprietary rights embodied in any of said United States or foreign patents or
patent applications.

     1.7  "TECHNOLOGY" shall mean all ideas, know-how, trade secrets, data,
inventions, developments, formulas, processes, techniques, discoveries and any
other proprietary rights in and to the technology described in Exhibit B
attached hereto.

     1.8  "VALID CLAIM" shall mean a claim in a pending application for which
five years shall not have passed from the initial application date or a claim in
an issued patent that has not been declared invalid by an unappealed or an
unappealable decision of a court of competent jurisdiction.

                               ARTICLE 2 - GRANT

     2.1  Grant.  UKRF hereby grants to LICENSEE, subject to the terms herein
recited, an exclusive, nontransferable (except as provided in Article 10
herein), perpetual, royalty bearing, worldwide right and license, with the right
to grant sublicenses, to make, have made, use, sell and distribute (directly or
indirectly through third parties) LICENSED PRODUCTS and to use the TECHNOLOGY
and the PATENT RIGHTS.

     2.2  Delivery.  Promptly after the EFFECTIVE DATE and thereafter upon
reasonable notice, UKRF shall deliver to LICENSEE all data, documentation, and
other physical embodiments of the PATENT RIGHTS and TECHNOLOGY together with all
cooperation, assistance and access to data reasonably requested by LICENSEE to
effect transfer of the TECHNOLOGY.

     2.3  Due Diligence.  LICENSEE shall use all commercially reasonable efforts
to develop, commercialize and actively market LICENSED PRODUCTS based upon the
PATENT RIGHTS throughout the life of this agreement.  LICENSEE shall strive to
file an INDA with the FDA within three years from the date of this agreement,
initiate a phase three clinical study within eight years from the date of this
agreement, and achieve a first commercial sale of LICENSED PRODUCT within eleven
years from the date of this agreement.  If, as a result of events beyond the
reasonable control of the parties, achievement of the first or second milestones
is delayed, the parties shall negotiate mutually agreeable extensions of
subsequent milestones.

                          ARTICLE 3 - CONFIDENTIALITY

     3.1  UKRF.  Because LICENSEE has revealed, and may in the future reveal, to
UKRF, the University of Kentucky and certain employees, professors, technicians,

                                       3
<PAGE>

consultants, visiting scientists, students, and post doctoral associates of the
University of Kentucky or UKRF (collectively the "Researchers") in the course of
this Agreement certain confidential knowledge, know-how, practices, processes,
or other information (hereinafter referred to as "CONFIDENTIAL INFORMATION"),
UKRF agrees to hold in confidence and shall require the University of Kentucky,
UKRF's other AFFILIATES, and the Researchers, their respective employees,
students and agents to hold in confidence, by using a reasonable degree of care,
any CONFIDENTIAL INFORMATION which is identified at the time of disclosure as
"CONFIDENTIAL" and, in the case of oral disclosures, is identified in writing
within 30 days as confidential, and UKRF agrees not to disclose and shall
require the University of Kentucky, UKRF's other AFFILIATES, their respective
employees, students and agents, and the Researchers not to disclose CONFIDENTIAL
INFORMATION to any third party without the express written consent of LICENSEE.
(UKRF agrees to cooperate with LICENSEE in obtaining suitable confidentiality
agreements from persons as may be deemed necessary by LICENSEE.)  This
requirement shall remain in force for a period of five (5) years following
termination of this Agreement, or until the expiration of the last expiring
patent associated with the Confidential Information, whichever shall occur
later.  Nothing in this paragraph shall in any way restrict the rights of UKRF,
the University of Kentucky, UKRF's other AFFILIATES, their respective employees,
students or agents, or the Researchers to use, disclose or otherwise deal with
any information which:

          (a) Can be demonstrated to have been in the public domain as of the
     effective date of this Agreement or comes into the public domain during the
     term of this Agreement through no act of the recipient; or

          (b) Can be demonstrated to have been independently known to the
     recipient prior to the receipt thereof, or made available to the recipient
     as a matter of lawful right by a third party; or

          (c) Can be demonstrated to have been rightfully received by the
     recipient after disclosure under this Agreement from a third party who did
     not require the recipient to hold it in confidence or limit its use and who
     did not acquire it, directly or indirectly, from LICENSEE under a
     continuing obligation of confidentiality; or

          (d) Shall be required for disclosure to any governmental regulatory
     agencies pursuant to approval for use; or

          (e) Is independently conceived, invented or acquired by researchers of
     the recipient who have not been personally exposed to the information
     provided to the recipient hereunder; or

          (f) Is published by a governmental agency as part of the normal patent
     filing and prosecution process.

                                       4
<PAGE>

     3.2  LICENSEE.  Because UKRF or the Researchers have revealed, and may in
the future reveal, to LICENSEE in the course of this Agreement certain
CONFIDENTIAL INFORMATION, LICENSEE agrees to hold in confidence and shall
require LICENSEE's AFFILIATES, their respective employees and agents to hold in
confidence, by using a reasonable degree of care, any CONFIDENTIAL INFORMATION
which is identified at the time of disclosure as "CONFIDENTIAL" and, in the case
of oral disclosures, is identified in writing within 30 days as confidential,
and LICENSEE agrees not to disclose and shall require LICENSEE's AFFILIATES,
their employees and agents not to disclose CONFIDENTIAL INFORMATION to any third
party without the express written consent of UKRF. (LICENSEE agrees to cooperate
with UKRF in obtaining suitable confidentiality agreements from persons as may
be deemed necessary by UKRF.)  This requirement shall remain in force for a
period of five (5) years following termination of this Agreement, or until the
expiration of the last expiring patent associated with the Confidential
Information, whichever shall occur later.  Nothing in this paragraph shall in
any way restrict the rights of LICENSEE, the LICENSEE's AFFILIATES, their
respective employees or agents to use, disclose or otherwise deal with any
information which:

          (a) Can be demonstrated to have been in the public domain as of the
     effective date of this Agreement or comes into the public domain during the
     term of this Agreement through no act of the recipient; or

          (b) Can be demonstrated to have been independently known to the
     recipient prior to the receipt thereof, or made available to the recipient
     as a matter of lawful right by a third party; or

          (c) Can be demonstrated to have been rightfully received by the
     recipient after disclosure under this Agreement from a third party who did
     not require the recipient to hold it in confidence or limit its use and who
     did not acquire it, directly or indirectly, from UKRF or PRINCIPAL
     INVESTIGATOR under a continuing obligation of confidentiality; or

          (d) Shall be required for disclosure to any governmental regulatory
     agencies pursuant to approval for use; or

          (e) Is independently conceived, invented or acquired by researchers of
     the recipient who have not been personally exposed to the information
     provided to the recipient hereunder;

          (f) Is published by a governmental agency as part of the normal patent
     filing and prosecution process; or

                                       5
<PAGE>

          (g)  May be disclosed to a third party pursuant to or in connection
     with a license agreement between LICENSEE and such third party and such
     disclosure is covered under a suitable confidentiality agreement.

                   ARTICLE 4 - REPRESENTATIONS AND WARRANTIES

     4.1  Ownership.  UKRF warrants that it is the owner of the PATENT RIGHTS
and TECHNOLOGY and that any resultant patents are free of any liens,
encumbrances, restrictions and other legal or equitable claims.

     4.2  Authority.  Each party represents and warrants that it has the right
          ---------
and authority to enter into this Agreement.

     4.3  Conflicts.
          ---------

          (A)  UKRF represents and warrants that the making of this Agreement
     does not violate any separate agreement it has with any other person or
     entity.  UKRF further represents and warrants that it has not granted any
     rights or licenses to the TECHNOLOGY or PATENT RIGHTS, or any portion
     thereof, to any party.

          (B)  LICENSEE represents and warrants that the making of this
     Agreement does not violate any separate agreement it has with any other
     person or entity.

     4.4  Exceptions.  Nothing in this Agreement shall be construed as:
          ----------

          (A) conferring rights on UKRF to use in advertising, publicity or
     otherwise the name of LICENSEE or of its employees, AFFILIATES or
     sublicensees without the prior written approval of LICENSEE, which shall
     not be unreasonably withheld; and

          (B) conferring rights on LICENSEE to use in advertising or publicity
     the names of "University of Kentucky" UKRF, their affiliates or their
     employees without the prior written approval of UKRF.

     4.5  Disclaimer.  EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEITHER PARTY MAKES
ANY REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED.  THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE.

                                       6
<PAGE>

[*]=CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETED ASTERISKS HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                             ARTICLE 5 - ROYALTIES

     5.1  Royalties.  Beginning with the FIRST COMMERCIAL SALE and subject to
the terms hereof, LICENSEE agrees to pay to UKRF, as consideration for the
rights granted under this Agreement:

          (A) An amount equal to [*] of NET ROYALTIES from LICENSED PRODUCTS
     developed by LICENSEE's sublicensees and sold in the United States;

          (B) An amount equal to [*] of NET ROYALTIES from LICENSED PRODUCTS
     developed by LICENSEE's sublicensees and sold outside of the United States;
     and

          (C) An amount equal to [*] of the NET SALES of LICENSED PRODUCTS sold

     For purposes of determining the royalty rate, all product dosage forms,
formulations, clinical indications and applications based on a particular
principal active ingredient or combinations thereof shall be considered a single
LICENSED PRODUCT for such purpose.

     5.2  Royalty Period.  The obligation to pay royalties under Section 5.1
          --------------
shall continue for the following periods:

          (A) With respect to sales of LICENSED PRODUCTS subject to such
     royalties, except as otherwise set forth in Section 5.7 hereof, for the
     life of such patents until the last of said patent rights covering such
     products, its use or its manufacturing expires, after which LICENSEE's
     license under Article 2 above shall become fully paid-up and royalty-free.

          (B) With respect to sales of LICENSED PRODUCTS subject to such
     royalties which make use of all or a portion of the TECHNOLOGY which are
     not covered by PATENT RIGHTS, for a period of five (5) years from the date
     of first sale of such LICENSED PRODUCT, after which time LICENSEE's license
     under Article 2 above shall become fully paid-up and royalty free.
     Notwithstanding the foregoing, in the event that the TECHNOLOGY used in a
     LICENSED PRODUCT comes into the public domain through no act of LICENSEE,
     LICENSEE's license under Article 2 above shall become fully paid-up and
     royalty free.

     5.3  Payments.  Royalties will be due and payable with each report
submitted in accordance with Section 6.2.  Royalty payments shall be made in
United States dollars in Lexington, Kentucky or at such other place as UKRF may
reasonably designate; provided, however, that if the laws and regulations
controlling in any foreign country prevent a royalty

                                       7
<PAGE>

[*]=CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETED ASTERISKS HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

payment to be made in Lexington, Kentucky, or at UKRF's designated place or
prevent a royalty payment in United States dollars, UKRF agrees to accept such
royalty in the form and place as permitted, including deposits by LICENSEE in
the applicable foreign currency in a local bank or banks designated by UKRF. If
any currency conversion is required in connection with the payment of royalties
hereunder, such conversion shall be made by using the exchange rate prevailing
at a first-class foreign exchange bank on the last business day of the calendar
biannual reporting period to which such royalty payments relate. If laws or
regulations require the withholding of income taxes owed by UKRF on account of
royalties accruing under this Agreement, such taxes shall be deducted on a
country-by-country basis by LICENSEE from such remittable royalty and will be
paid by it to the proper taxing authority. Proof of payment shall be secured and
sent to UKRF as evidence of such payment.

     5.4  Multiple Royalties.  No multiple royalties shall be payable because
LICENSED PRODUCTS, their manufacture, use or sale shall be covered by more than
one patent application or patent licensed under this Agreement.  In the event
that a LICENSED PRODUCT'S manufacture, use or sale shall be covered by one or
more patent application or patent licensed under this Agreement and by one or
more patent application or patent license under any other agreement between
LICENSEE and UKRF or the University of Kentucky, (together with this Agreement,
the "Multiple License Agreements"), LICENSEE shall pay the highest of the agreed
upon royalty rate applicable for such LICENSED PRODUCT under any of the Multiple
License Agreements plus [*] of the second highest agreed upon royalty rate under
any of the other Multiple License Agreements.

     In the event that a LICENSED PRODUCT's manufacture, use or sale shall be
covered by one or more patent application or patent licensed under this
Agreement and by one or more patent application or patent licensed under any
other agreement between LICENSEE and one or more third parties (not including
UKRF or University of Kentucky), then LICENSEE and UKRF shall negotiate in good
faith to determine the applicable royalty rate payable to UKRF for such LICENSED
PRODUCT hereunder.

     5.5  Competing Products.  If at any time during the term of this Agreement,
one or more competitors introduce in any country a product that competes with a
LICENSED PRODUCT, then the parties in good faith shall promptly review the facts
and circumstances, and if appropriate, negotiate an equitable adjustment to the
royalty rate on NET SALES of such LICENSED PRODUCT in that country.

     5.6 Invalid Patent.  In the event that no patent covering the LICENSED
PRODUCT shall have been issued in a given country within five (5) years from the
date of the initial patent application covering the LICENSED PRODUCT in such
country, no royalty shall be owed upon the sale of the LICENSED PRODUCT in such
country and sold for use in such country after said five (5) years.  In the
event that the only patent or patents covering the LICENSED PRODUCT in a given
country are declared invalid by an unappealed or unappealable decision of a
court of competent jurisdiction, the royalty payments thereafter due

                                       8
<PAGE>

under this Agreement by virtue of the sale of the LICENSED PRODUCT in said
country shall be at one-half the full rate which would otherwise be applicable
under this Agreement, and shall be due only until the period of royalty payments
in said country, prior to and after such adjustments, totals five (5) years. If
there are two or more conflicting judgments in courts of competent jurisdiction
of equal dignity with respect to the same patent, the decision more favorable to
the patent shall be followed until a less favorable decision has been followed
by the judgment of another court of competent jurisdiction and of higher
dignity.

                        ARTICLE 6 - REPORTS AND RECORDS

     6.1  Records.  LICENSEE and its sublicensees shall keep complete and
accurate books of account containing all particulars which may be reasonably
necessary for the purpose of showing the royalties payable to UKRF.  Said books
of account shall be kept at LICENSEE's principal place of business or the
principal place of business of a division of LICENSEE which is marketing
LICENSED PRODUCTS.  Said books and particulars shall be available during normal
business hours, upon reasonable notice, for two (2) years following the end of
the calendar year to which they pertain, to the inspection of an independent
certified public accountant retained by UKRF for the purpose of verifying
LICENSEE royalty statements.  Inspection shall be limited solely to those
matters directly related to LICENSEE royalty obligations under this Agreement
and shall be allowed no more than once a year.

     6.2  Delivery.  Within thirty (30) days after June 30 and December 31 of
each year, LICENSEE shall deliver to UKRF true and accurate reports, giving such
particulars of the business conducted by LICENSEE during the preceding six (6)
month period under this Agreement as are pertinent to a royalty accounting under
this Agreement.  These reports shall include at least the following:

          (A)  Total billings for LICENSED PRODUCTS sold;

          (B)  Deductions applicable;

          (C)  Total royalties due; and

          (D)  Name(s) and address(es) of all sublicensees.

     6.3  Audit Costs.  If an audit conducted on behalf of UKRF pursuant to
Section 7.1 reveals that LICENSEE has made an error of ten percent (10%) or more
in its favor in the aggregate payment due UKRF in any fiscal year of LICENSEE,
LICENSEE shall be obligated to pay the audit fee in connection with the audit.

     6.4  Marking.  LICENSEE and its sublicensees agree to mark all LICENSED
PRODUCTS sold in the United States with all applicable U.S. patent numbers.  All
LICENSED PRODUCTS shipped to or sold in other countries shall be marked in such
a manner as to conform with the patent laws and practice of the country to which
such products are shipped or in which such products are sold.

                                       9
<PAGE>

                 ARTICLE 7 - PATENT PROSECUTION AND ENFORCEMENT

     7.1  U.S. Applications.  LICENSEE hereby authorizes UKRF, in the name of
UKRF or its employees, at UKRF's expense, to apply for and seek prompt issuance
of, and upon issuance, maintain during the term of this Agreement U.S. patent
applications and patents as described in the PATENT RIGHTS or as may otherwise
apply to the TECHNOLOGY.  UKRF shall apply all reasonable efforts to retain
broad patent claims as are reasonable and practical taking into consideration
the need and likelihood of patent issuance and enforceability. LICENSEE shall
take all actions necessary to cooperate with and assist UKRF in the filing and
prosecution of such patent applications including but not limited to appropriate
invention disclosures and execution of documents as requested by UKRF's patent
counsel.  UKRF shall keep LICENSEE informed as to the status of such patent
applications including providing LICENSEE with copies of all written
communications with the patent offices, and consulting with LICENSEE on
responses to the patent offices in advance of submission.  If UKRF fails to
diligently pursue any of such patent applications and, within sixty (60) days of
LICENSEE's written request, fails to take such actions set forth in such request
respecting the prosecution of any of such patent applications or if UKRF
abandons any such patent application, LICENSEE shall have the right, at its
expense, to take such actions as are necessary to pursue such patent
applications, and LICENSEE shall have the right to offset against payments due
to UKRF hereunder until the expenses incurred by LICENSEE to pursue such patent
application have been recouped.

     7.2  Foreign Applications.  UKRF hereby authorizes LICENSEE, in the name of
UKRF or its employees, at LICENSEE's expense, to apply for and seek prompt
issuance of, and upon issuance, maintain during the term of this Agreement
foreign patent applications and patents as described in the PATENT RIGHTS or as
may otherwise apply to the TECHNOLOGY.  LICENSEE shall apply all reasonable
efforts to retain broad patent claims as are reasonable and practical taking
into consideration the need and likelihood of patent issuance and
enforceability.  UKRF shall take all actions necessary to cooperate with and
assist LICENSEE in the filing and prosecution of such patent applications
including but not limited to appropriate invention disclosures and execution of
documents as requested by LICENSEE's patent counsel.  LICENSEE shall keep UKRF
informed as to the status of such patent applications including providing UKRF
with copies of all written communications with the patent offices, and
consulting with UKRF on responses to the patent offices in advance of
submission.  If LICENSEE fails to diligently pursue any of such patent
applications and, within sixty (60) days of UKRF's written request, which shall
include submission to LICENSEE of an invention disclosure suitable for
implementing the action specified in the request, fails to take such actions set
forth in such request respecting the prosecution of any of such patent
applications or if LICENSEE abandons any such patent application, UKRF shall
have the right, at its expense, to take such actions as are necessary to pursue
such patent applications.  UKRF shall execute such documents as are reasonably
necessary to file with the Patent and Trademark Office notice of LICENSEE's
exclusive license under the PATENTS RIGHTS.

                                       10
<PAGE>

     7.3  Enforcement.  UKRF and LICENSEE shall each give immediate notice to
the other of any infringement of PATENT RIGHTS by third parties which may come
to their attention.  UKRF hereby grants to LICENSEE, at LICENSEE's expense, the
right to institute and conduct such legal action against third party infringers
of the PATENT RIGHTS and/or unauthorized users of the TECHNOLOGY, or enter into
such settlement agreements, as are deemed appropriate by LICENSEE.  LICENSEE
shall control the conduct of such litigation, including the choice of its
counsel.  LICENSEE shall receive the full benefits of any action it takes
pursuant to this Section 7.3.  In any such action, UKRF shall be entitled to
join LICENSEE as a party plaintiff and UKRF will be obligated to reasonably
assist at LICENSEE's expense.  In the event that such third party infringer or
such unauthorized user files a counterclaim or threatens to file a counterclaim
against  LICENSEE, LICENSEE hereby agrees to indemnify UKRF against all losses,
liabilities, claims, costs, charges and expenses incurred or suffered by UKRF in
connection with such counterclaim or threat to the extent that any such losses,
liabilities, claims, costs, charges and expenses arise because of LICENSEE'S
gross negligence, bad faith or wilful misconduct; provided, however, that
LICENSEE shall not be obligated to indemnify UKRF to the extent that any such
losses, liabilities, claims, costs, charges and expenses arise because of the
alleged infringement of the rights of such third party by reason of practice by
LICENSEE, its AFFILIATES or sublicensees of the license granted herein (the
parties agree that such alleged infringement and any indemnification relating
thereto shall be covered by Section 7.4).  Should LICENSEE fail to commence
actions or proceedings against infringers of the PATENTS or unauthorized users
of the TECHNOLOGY within ninety (90) days of receiving written notice thereof
from UKRF, UKRF, at UKRF's expense, shall have the right to initiate and pursue
such action and receive all resulting benefits.

     7.4  Infringement.  Subject to Section 5.6 hereof, in the event that a
claim or action for infringement of the rights of others is made or brought
against LICENSEE, its AFFILIATES or sublicensees during the term of this
Agreement, by reason of practice in such country by LICENSEE, its AFFILIATES or
sublicensees of the license granted herein, LICENSEE shall control the conduct
of such litigation, including the choice of its legal counsel, and shall pay all
costs and expenses, including attorneys fees, associated therewith. LICENSEE may
recover such costs and expenses and any judgment assessed against, or settlement
agreed upon by, LICENSEE by set-off against fifty percent (50%) of the amounts
payable to UKRF hereunder in any payment period.   Any amount remaining to be
offset from any period shall be carried forward until offset against royalties
for future periods.

                                       11
<PAGE>

                            ARTICLE 8 - TERMINATION

     8.1  Bankruptcy.  If LICENSEE undergoes a liquidation in bankruptcy, or
files a petition for liquidation in bankruptcy, or if the business of LICENSEE
shall be placed in the hands of a receiver, trustee or assignee for the benefit
of creditors, whether by the voluntary act of LICENSEE or otherwise, and if
LICENSEE fails to terminate any such proceeding within one hundred twenty (120)
days after its commencement, UKRF may at its election terminate this Agreement
upon thirty (30) days written notice to LICENSEE.  LICENSEE agrees to provide
written notice to UKRF of LICENSEE or a third party's intention to file a
petition for liquidation of LICENSEE in bankruptcy prior to such filing, if
known.

     8.2  Failure to Pay Royalties.  Should LICENSEE fail in its payment to UKRF
of royalties due in accordance with the terms of this Agreement, UKRF shall have
the right to serve notice upon LICENSEE by certified mail at an address
designated in Article 12 hereof, of its intention to terminate this Agreement
within ninety (90) days after receipt of said notice of termination unless
LICENSEE shall pay UKRF within the ninety (90) day period.  If such ninety (90)
day period expires and if the amount of royalties due is not paid by LICENSEE,
the rights, privileges and license granted hereunder shall terminate upon the
end of such ninety (90) day period.

     8.3  Material Breach.  Upon any other material breach or default by
LICENSEE, UKRF shall have the right to terminate this Agreement and the rights
and license granted hereunder by ninety (90) days' notice by certified mail to
LICENSEE.  Such termination shall become effective at the end of such ninety
(90) day period unless LICENSEE has cured any such breach or default prior to
the expiration of the ninety (90) day period.

     8.4  Termination by LICENSEE.  LICENSEE may terminate this Agreement upon
one hundred twenty (120) days' notice by certified mail to UKRF.

     8.5  Obligations on Termination:  Upon termination of this Agreement for
any reason, nothing herein shall be construed to release either party of any
obligation which matured prior to the effective date of such termination, and
LICENSEE may, after the effective date of such termination, complete LICENSED
PRODUCTS in the process of or manufacture at the time of such termination and
sell the same together with LICENSED PRODUCTS in inventory for a period of one
year, provided that LICENSEE pays to UKRF royalties as required by Article 5 of
this Agreement and submits the reports as required by Article 6 on the sale of
LICENSED PRODUCTS.

     8.6  Survival.  Articles 3 and 4 and Sections 7.3, 7.4, 8.5, 9.1, 9.2, 9.3
and 13.1 shall survive termination of this Agreement as well as the right of
UKRF to collect any accrued royalties as recited in Article 5.

                                       12
<PAGE>

     8.7  Sublicenses.  In the event the licenses granted to LICENSEE under
Section 2 above terminate for any reason, each of LICENSEE'S sublicenses in
effect at such time shall continue in accordance with the terms of such
sublicenses.  UKRF agrees that each such sublicensee shall be entitled to
enforce such rights and license directly against UKRF.  The foregoing shall be
subject to each such sublicensee agreeing in writing at any time prior to such
terms and conditions are to become effective that UKRF is entitled to enforce
the provisions in such sublicense directly against such sublicensee.

                          ARTICLE 9 - INDEMNIFICATION

     9.1  Indemnification by Licensee. LICENSEE shall at all times during the
term of this Agreement and thereafter, indemnify, defend and hold UKRF, its
trustees, officers, employees and affiliates, harmless against all claims and
expenses, including legal expenses and reasonable attorneys' fees, arising out
of the death of or injury to any person or persons or out of any damage to
property and against any other claim, proceeding, demand, expense and liability
of any kind whatsoever resulting from the production, manufacture, sales, use,
consumption or advertisement of the LICENSED PRODUCTS or arising from any
obligation of LICENSEE hereunder.

     9.2 Insurance.  If LICENSEE produces, manufactures or sells any LICENSED
PRODUCTS, LICENSEE will maintain product liability insurance, with an
endorsement naming UKRF, the University of Kentucky, its Board of Trustees,
agents officers and employees as additional insureds covering liabilities for
the production, manufacture and/or sale of the LICENSED PRODUCT.  The policy of
insurance shall contain a provision of non-cancellation except upon the
provision of thirty (30) days notice to the University.  Policy limits shall be
not less than $1,000,000 per occurrence.

     9.3 Sublicensees.  If LICENSEE sublicenses any of the rights, privileges
and licenses granted hereunder, LICENSEE shall require the sublicense to provide
UKRF evidence of such product liability insurance.

                            ARTICLE 10 - ASSIGNMENT

     Neither party will assign or transfer its rights and obligations under this
Agreement except with the consent of the other party which consent shall not be
unreasonably withheld or delayed, provided that any such assignee or transferee
must as a condition to such assignment agree in writing to be bound by the terms
and provisions of this Agreement.  Upon such assignment or transfer and
agreement by such assignee or transferee, the term LICENSEE or UKRF, as the case
may be, as used herein shall mean such assignee or transferee.

                                       13
<PAGE>

                              ARTICLE 11 - AGENCY

     Neither party shall be deemed to be an agent of the other party as a result
of any transaction under or related to this Agreement, and shall not in any way
pledge the other party's assets or incur any obligation on behalf of the other
party.

               ARTICLE 12 - PAYMENTS, NOTICES AND COMMUNICATIONS

     Any payment, notice or other communication pursuant to this Agreement shall
be sufficiently made or given on the date of mailing if sent to such party by
certified first class mail, postage prepaid, addressed to it at its address
below or as it shall designate by written notice given to the other party:

     In the case of UKRF:      The University of Kentucky
                               Research Foundation
                               11 Administration Building
                               Lexington, Kentucky  40506-0032
                               Attention:  Dr. Fitzgerald Bramwell

     In the case of LICENSEE:  Control Delivery Systems, Inc.
                               86 Rosedale Road
                               Watertown, MA  02172
                               Attention:  President

                     ARTICLE 13 - MISCELLANEOUS PROVISIONS

     13.1  Limitation of Liability.  Neither party shall be liable to the other
for any special, consequential, incidental or indirect damages arising out of
this agreement, however caused, under any theory of liability.

     13.2  Governing Law.  This Agreement shall be construed, governed,
interpreted and applied in accordance with the laws of the Commonwealth of
Kentucky, except that questions affecting the construction and effect of any
patent shall be determined by the law of the country in which the patent was
granted.  The parties hereto further agree that any and all proceedings relating
to the subject matter hereof may be maintained in the State and Federal Courts
of the Commonwealth of Kentucky, which courts shall have non-exclusive
jurisdiction for such purpose.

                                       14
<PAGE>

     13.3  Confidentiality of Agreement.  Each party agrees that the terms and
conditions of this Agreement shall be treated as confidential information except
as required by or for the University of Kentucky's standard funding disclosure
policies, applicable disclosure laws, financing sources, enforcement of the
Agreement, mergers and acquisitions, or as otherwise mutually agreed by the
parties.

     13.4  Entire Agreement. The parties hereto acknowledge that this instrument
sets forth the entire agreement and understanding of the parties hereto as to
the subject matter hereof, and shall not be subject to any change or
modification except by the execution of a written instrument subscribed to by
the parties hereto.

     13.5  Severability.  The provisions of this Agreement are severable, and in
the event that any provisions of this Agreement are determined to be invalid or
unenforceable under any controlling body of law, such invalidity or
enforceability shall not in any way affect the validity or enforceability of the
remaining provisions hereof.

     IN WITNESS WHEREOF, the parties hereto have hereunder set their hands and
seals and duly executed this Agreement as of the day and year first above
written.

UNIVERSITY OF KENTUCKY                 CONTROL DELIVERY SYSTEMS, INC.
  RESEARCH FOUNDATION

By  /s/ Joseph L. Fink, III             By  /s/ Paul Ashton
    --------------------------------        -----------------------------------

Name  Joseph L. Fink, III               Name  Paul Ashton
      ------------------------------          ---------------------------------

Title  Associate Vice President for     Title  President
       -----------------------------           --------------------------------
       Research and Graduate Studies
       -----------------------------

                                       15
<PAGE>

                                   Exhibit A

                                 PATENT RIGHTS

United States Patent Serial No. 08/534,854

Title: Implantable Controlled Release Device to Deliver Drugs to an Internal
       ---------------------------------------------------------------------
Portion of the Body;
-------------------

Author:  Paul Ashton, et al;
                      -- --

and all foreign counterparts

                                       16
<PAGE>

                                   Exhibit B

                                   TECHNOLOGY

     (i)   All materials and methods used or useful in the development and
manufacture of all the compounds listed in the U.S. patent described in Exhibit
A hereto (the "Compounds"),

     (ii)  all published and unpublished materials, including but not limited
to, research data, human clinical data, other test results and know-how,
relating to the Compounds,

     (iii) all reference spectra relating to the Compounds,

     (iv)  all production procedures of spectra relating to the Compounds,

     (v)   all molding device designs relating to the Compounds,

     (vi)  all manufacturing scale up know-how relating to the Compound, and

     (vii) all samples of the Compounds.

                                       17<PAGE>

                                                                   Exhibit 10.9
                       LICENSE AND DEVELOPMENT AGREEMENT
                       ---------------------------------

     This Agreement is made as of December 31, 1992 by and between Control
Delivery Systems, Inc., a Delaware corporation ("CDS") and Chiron IntraOptics,
Inc. a Delaware corporation ("CIO").

                                   BACKGROUND
                                   ----------

    A.  CDS has obtained an exclusive, worldwide License from the University of
Kentucky Research Foundation ("UKRF") to the Licensed Patent Rights (as defined
herein) relating to certain sustained release drug delivery devices which have
particular application to ophthalmic diseases, and has developed expertise in
performing research and development relating to such devices.

    B.  CIO is in the business of developing and commercializing products for
ophthalmic applications, and has established an extensive sales force trained in
servicing the requirements of ophthalmic surgeons.

    C. CIO is entering into separate agreements with CDS, dated the date hereof,
pursuant to which, inter alia, CIO will purchase 30,000 shares of Common Stock
of CDS.

    D. CIO desires to obtain an exclusive license to certain technology owned or
controlled by CDS, including an exclusive sublicense under CDS's license from
UKRF, to obtain rights to negotiate licenses for additional CDS technology and
products, and to collaborate with CDS on the development of certain ophthalmic
products. CDS and CIO desire to enter into an agreement relating to such
matters.

    NOW THEREFORE, in consideration of the mutual agreements provided herein,
CDS and CIO agree as follows:

1.  Definitions
    -----------

    1.1  "Affiliate" shall mean any corporation, or other entity controlling,
controlled by or under common control with a party to this Agreement. For such
purpose "control" shall mean the ownership, directly or indirectly, of 50% or
more of the voting stock of a corporate entity, or of 50 % or more of the
beneficial interest of an entity other than a corporation.

    1.2  "FDA" shall mean the United States Food and Drug Administration, or a
successor to such agency.

    1.3 "INDA" shall mean an investigational new drug application and associated
documents required to be filed with the FDA in order to obtain approval to
commence human clinical trials of a product.

    1.4  "Initial Ophthalmic Products" shall mean three Licensed Products for
Ophthalmic Applications each of which contain one of the following as the
principal active ingredient: (i) intravitreal ganciclovir, (ii) subconjunctival
5FU, and (iii) intravitreal cyclosporine, or such other active ingredients as
<PAGE>

shall be mutually agreed upon by CDS and CIO. "Principal active ingredient", as
used herein, shall mean a chemical or biological compound which acts upon the
primary disease process being treated as defined by claims made under the new
drug application filed with the FDA for such product.

    1.5 "Know-How" shall mean any knowledge and proprietary information which is
not generally publicly known, including without limitation all preclinical,
clinical, chemical, biochemical, toxicological, manufacturing, formulation and
scientific research information, whether or not capable of precise separate
description but which alone or when accumulated gives to the one acquiring it an
ability to study, test, produce, formulate or market something which one
otherwise would not have known to study, test, produce, formulate or market in
the same way.

    1.6 "Licensed Know-How" shall mean any and all Know-How owned or controlled
by CDS which is necessary or useful for making, using or selling the Licensed
Products, including but not limited to in vitro, preclinical and clinical data,
regulatory filings, and manufacturing information.

    1.7 "Licensed Patent Rights" shall mean United States Patent Application
Serial Number 07/658,695, any corresponding foreign patent application, and any
continuation, continuation-in-part, divisions, reissues or extensions of the
foregoing, and any patents issuing from any of the foregoing applications.

    1.8 "Licensed Product(s)" shall mean a sustained-release drug delivery
system for use in Ophthalmic Applications, the manufacture, use or sale of which
would, in the absence of a license, infringe a claim contained in the Licensed
Patent Rights.

    1.9  "Licensed Process(es)" shall mean the process or processes of using a
Licensed Product in Ophthalmic Applications, which use would, in the absence of
a license, infringe a claim contained in the Licensed Patent Rights.

    1.10 "NDA" shall mean a New Drug Application and associated documents
required to be filed with the FDA in order to obtain approval to market a
particular product.

    1.11  "Net Sales" shall mean the amount invoiced for sales, leases or other
dispositions of Licensed Products or Licensed Processes hereunder (other than
sales, leases or other dispositions to Affiliates unless such Affiliate is the
end user), less the following deductions (to the extent they are not already
reflected in the amount billed):

              a) Discounts, uncollectible debt, and wholesaler chargebacks
          allowed and taken in amounts customary in the trade;
              b) Import, export, excise, sales or use taxes, tariffs or duties
          directly imposed and with reference to particular sales;
              c) Outbound transportation prepaid or allowed; and
              d) Amounts allowed or credited on returns or retroactive price
          reductions. No deduction shall be made (i) for commissions paid to
          individuals whether they be with independent sales agencies or
          regularly employed by CIO, (ii) for cost of collections, or (iii) for
          royalties, fees or other costs of drug acquisition paid to holders of
          licenses or patents

                                       2
<PAGE>

          for drugs used in connection with the Licensed Products or Licensed
          Processes. Licensed Products) or Licensed Process(es) shall be
          considered "sold" when billed out or invoiced to a third party. If a
          Licensed Product is incorporated into another product or is sold in
          combination with other products and not invoiced separately, such
          Licensed Product shall be included in Net Sales at the then current
          list price for such quantities of such Licensed Product with any
          discount from list price being applied proportionately to the discount
          from list price of the Product into which the Licensed Product was
          incorporated or the list price of the other products sold, as the case
          may be.

    1.12  "Ophthalmic Applications" shall mean methods or products used for the
purpose of treatment, diagnosis, mitigation or prevention of a disease or
condition relating to the eye or to vision.

    1.13  "UKRF" shall mean the University of Kentucky Research Foundation.

    1.14 "UKRF License" shall mean that certain License Agreement, dated October
20, 1991, between URRF and CDS, relating to the Licensed Patent Rights as such
agreement may be amended in the future pursuant to the terms hereof.

2.  License Grants
    --------------

    2.1 Subject to the terms and conditions of this Agreement, CDS hereby grants
to CIO and its Affiliates a sole and exclusive worldwide license (including an
exclusive sublicense under the UKRF License), under the Licensed Patent Rights
and Licensed Know-How, to make, use, lease and sell the Licensed Products and
Licensed Processes for Ophthalmic Applications. CIO shall have the right to
sublicense its rights hereunder; provided, however, that for five years after
the date of this Agreement, CIO shall not, without the written consent of CDS
(which consent shall not be unreasonably withheld or delayed), enter into a
sublicense agreement relating to rights in the United States which .agreement
would result in CIO having no direct involvement in manufacturing, marketing or
regulatory activity concerning Licensed Products. Without limiting the
generality of the foregoing, CDS includes in such license to CIO any and all of
its rights and interests in the Initial Ophthalmic Products. CDS further agrees
to refrain from asserting against CIO, with respect to CIO's activities licensed
hereunder, any other patent or proprietary right owned or controlled by CDS
which covers the Licensed Products, Licensed Processes or Licensed Know-How that
might otherwise be infringed by CIO in making, using or selling Licensed
Products and Licensed Processes hereunder. The parties acknowledge that CDS
retains its rights in the Licensed Patent Rights and the Licensed Know-How for
applications other than Ophthalmic Applications.

    2.2 CDS shall maintain the UKRF License in full force and effect and shall
not amend or modify the UKRF License without CIO's written consent, which
consent CIO shall not unreasonably withhold or delay.

    2.3 Notwithstanding the license grant in Section 2.1, CDS hereby retains and
reserves a nonexclusive, non-transferable royalty-free right and license under
the Licensed Patent Rights and Licensed Know-How solely for research use
involving Ophthalmic Applications, but not for making, using or selling any
commercial products or processes for Ophthalmic Applications.

                                       3
<PAGE>
[*]=CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETED ASTERISKS HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

    2.4 If, during the term of this Agreement, CIO determines, in its
discretion, not to pursue development or commercialization (either through its
own development effort or through licensing others for such purpose) of any
Licensed Products for a particular disease or condition included within
Ophthalmic Applications, then CIO shall so notify CDS, and if CDS notifies CIO,
within 60 days after such notice from CIO, that it desires a license under the
Licensed Patent Rights to develop a product for that same disease or condition,
then CIO shall grant CDS a nonexclusive, transferable, royalty-free sublicense
for such application provided that CDS shall not grant any sublicense on royalty
terms more favorable than those granted to CIO in this Agreement. Such license
to CDS shall cover only the Licensed Patent Rights, and not any other
proprietary rights of CIO.

3.  Payments and Royalties
    ----------------------

    In consideration of the license rights granted to CIO under Section 2, CIO
shall make the following payments to CDS:

    3.1 On the date of this Agreement, CIO shall pay CDS an initial license fee
in the amount of one million, nine hundred thousand dollars ($1,900,000) as a
one-time license fee; provided, however, that one-half of such payment shall
automatically convert into an advance payment of royalties, which shall be fully
creditable against any earned royalties that would otherwise become payable
hereunder, if at (or before) the time CIO obtains regulatory approval to market
its first Licensed Product in the United States, the United States Patent and
Trademark Office has not issued a patent from U.S. Patent Application Serial
Number 07/658,695, which patent shall contain claims substantially the same as
those set forth in Exhibit 3.1.

    3.2 CIO shall pay to CDS a royalty equal to a percentage, as set forth
below, of the cumulative Net Sales of each licensed Product by CIO and .its
Affiliates and sublicensees: [*] of Net Sales for the first [*] of Net Sales of
the relevant Licensed Product; [*] of Net Sales of such Licensed Product for the
next [*] in Net Sales of the relevant Licensed Product; and [*] of Net Sales of
such Licensed Product on all Net Sales of such Licensed Product after [*] in Net
Sales for such Licensed Product have been achieved. For purposes of determining
the applicable royalty rate, Net Sales of CIO and its Affiliates and
sublicensees shall be aggregated, and cumulated from the commencement of sales
of each product, on a worldwide, product-by-product basis, and all product
dosage forms, formulations, clinical indications and applications based on a
particular principal active ingredient shall be considered a single Licensed
Product for such purpose. Such royalty payment obligations shall be subject to
credits and adjustments as set forth in this Agreement, and all credits shall be
carried forward until fully utilized.

    3.3 CIO shall also pay to CDS any royalty amounts owing from CDS to UKRF
under the UKRF License with respect to sales of Licensed Products under this
Agreement; provided, however, that such payments shall in no event exceed

                                       4
<PAGE>

[*]=CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETED ASTERISKS HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

[*] of Net Sales. Notwithstanding the foregoing, if UKRF shall deliver a
notice of nonpayment of royalties pursuant to Section 7.2 of the UKRF License,
CIO shall have the right to make such payments directly to UKRF until such time
as CIO shall be reasonably satisfied with CDS' ability to pay.

    3.4 If at any time during the term of this Agreement, one or more
competitors introduce in any country a product that competes with a Licensed
Product and uses a control delivery system substantially similar to that used in
the Licensed Products, then the parties shall promptly negotiate an equitable
adjustment to the royalty rate on Net Sales of such Licensed Product in that
country. In determining the appropriate royalty adjustment under this Section
3.4, the parties shall take into account the extent to which royalties have been
adjusted as to the same Licensed Product in the same country pursuant to the
provisions of Section 6.5. The parties shall attempt for 60 days from notice to
CDS by CIO of such competing product to reach agreement on any adjustment
provided for in this Section 3.4, and if, at the end of such 60-day period, such
negotiations have not resulted in an agreement, then either CIO or CDS may
elect, by written notice to the other, to have the matter finally settled by an
arbitration to take place in accordance with the Commercial arbitration rules of
the American Arbitration Association ("AAA"). There shall be one arbitrator
selected by mutual agreement of CDS and CIO or if they are unable to agree by
the AAA. The arbitrator shall hear evidence and shall have the power to order
production of such documents from CIO and CDS as the arbitrator shall determine
necessary.

    3.5 Notwithstanding anything herein to the contrary, (i) the obligation to
pay royalties is to be imposed only once with respect to any particular unit of
the applicable Licensed Product or Licensed Process, regardless of the number of
Licensed Patent Rights covering the same, and (ii) no additional royalty shall
be payable as to a Licensed Process to the extent such process is performed
using units of Licensed Product for which a royalty is paid.

4.  Royalty Reports and Payments
    ----------------------------

    4.1 During the term of this Agreement and for so long thereafter as is
required to report royalties payable under Section 13.3, CIO shall deliver to
CDS within 60 days after March 31, June 30, September 30, and December 31 of
each year a report, showing total billings for each Licensed Product, deductions
from Net Sales, total royalties due and any credits permissible pursuant to this
Agreement. Simultaneously with the delivery of each such report, CIO shall pay
to CDS the royalty payments due under this Agreement for the period covered by
such report. If no royalties are due, it shall be so reported. Late payments
shall bear interest at the rate of twelve percent per annum.

    4.2 Royalties shall be paid in United States dollars to CDS at CDS's address
for notice specified in Section 14.3 hereof, or at such other place as CDS may
reasonably designate by notice consistent with the applicable laws and
regulations of any foreign jurisdiction. The Net Sales amount calculated
hereunder shall first be determined in the currency in which the Licensed
Product was sold and then converted into its equivalent in United States
currency at the average monthly conversion rate for such foreign currency
computed base on the conversion rates as published in the Wall Street Journal
for the last month of the accounting period for the report, made under section
4.1 above.

    4.3 If the law or regulation of any country shall at any time operate to
prohibit the transfer of funds therefrom to CDS, CIO shall notify CDS to such
effect and (provided that CIO shall first attempt in good faith to follow CDS's

                                       5
<PAGE>

instructions pursuant to the first sentence of Section 4.2) shall have the right
to pay or cause to be paid royalties hereunder on account of its sales and the
sales of its Affiliates and sublicensees in such country by depositing local
currency (if CIO is paid in such currency) to the account of CDS in an interest-
bearing account if permissible at the prevailing commercial interest rate in a
bank in such country (which account and bank are reasonably acceptable to CDS).
CIO shall thereafter cooperate with CDS in CDS's efforts to obtain the lawful
release of said funds to CDS, but shall have no further responsibility therefor.

          If laws or regulations require the withholding of income taxes owed by
CDS on account of royalties accruing under this Agreement, such taxes shall be
deducted on a country-by-country basis by CIO from such remittable royalty and
will be paid by it to the proper taxing authority. Proof of payment shall be
secured and sent to CDS as evidence of such payment.

    4.4 For a period not less than five years after the relevant period of sales
CIO shall keep full true, and accurate books of account sufficient to determine
Net Sales for each Licensed Product and the royalties due hereunder. CDS shall
have the right not more than once during any calendar year, to have the books
and records of CIO and such Affiliates that sell Licensed Products audited by a
qualified independent accounting firm of its choosing, under appropriate
confidentiality provisions, to ascertain the accuracy of the reports and
payments hereunder and compliance by CIO and such Affiliates with their
obligations under this Agreement. Such audit shall be conducted upon at least 20
days advance notice during normal business hours and in a manner that does not
interfere unreasonably with their business. In the event any such audit
determines that the reported Net Sales were less than 90% of actual Net Sales
for the period in question, then the reasonable costs of such audit shall be
borne by CIO and CDS shall have the right to conduct such audits once every six
months during the next succeeding calendar year. In all other events the costs
shall be borne by CDS. CIO shall pay interest at a rate of twelve percent per
annum on any delinquent royalty payments shown to be owing to CIO as a result of
such audit.

5.  Patent Rights
    -------------

    5.1 CDS shall file, prosecute and maintain, and pay the cost thereof, of all
Licensed Patent Rights in the United States, or shall cause UKRF to do the same.
CDS shall file, prosecute and maintain at CIO's expense all Licensed Patent
Rights in the foreign jurisdictions listed in Exhibit 5.1 and in such other
jurisdictions as CIO determines. However, notwithstanding the foregoing, if CDS
determines not to file or continue to prosecute any such applications, or to
maintain in effect any patent resulting from any of such applications, then CDS
shall promptly so notify CIO in writing, and CIO shall have the option to file,
prosecute or, maintain such patent applications at its expense, in which case
CDS shall assign it rights to such applications and patents to CIO without any
further consideration therefor. CDS shall advise CIO in a timely manner as to
the status of all patent applications included in Licensed Patent Rights, and
upon request provide CIO with copies of the complete patent prosecution files of
such patent applications and patents issued therefrom.

    5.2 CDS shall (or shall cause UKRF to), at all times during the life of
Licensed Patent Rights, provide CIO in a timely manner with copies of all
material notices and correspondence from governmental departments, agencies and
courts pertaining to matters covered in such patents or patent applications,
including but not limited to notices of tax and maintenance payments due.

                                       6
<PAGE>

    5.3  In the event CDS shall at any time while this Agreement is in effect be
compelled by applicable law to issue licenses to other licensees for the
Licensed Products under the Licensed Patent Rights or Licensed Know-How, CDS
shall inform CIO of the order compelling any such licenses and shall renegotiate
the royalties and other payments required hereunder only with respect to the
country or countries wherein such compulsory licenses have been ordered so that
the renegotiated royalty and payment terms shall be no less favorable to CIO
than those granted to any third party under any such compulsory license.

6.  Infringement: Enforcement of Proprietary Rights
    -----------------------------------------------

    6.1  CIO shall inform CDS promptly of any alleged infringement involving
Ophthalmic Applications by third parties of any Licensed Patent Rights and
provide any information available to CIO relating to such alleged infringement.
CDS shall promptly investigate such alleged infringement and act diligently to
end any infringement of such rights, including but not limited to bringing suit
against such third-party infringer, or causing UKRF to take such steps. Unless
otherwise agreed by CDS and CIO, CDS shall bear the cost of any such
infringement suit commenced by CDS and shall keep any recovery derived
therefrom. CDS shall consult with CIO on the material aspects of such
litigation, and shall select counsel to which CIO has no reasonable objection.
No settlement, consent judgment or other voluntary final disposition of the suit
may be entered into without the consent of CIO, which consent shall not be
unreasonably withheld or delayed. CDS shall indemnify CIO against any order for
costs that may be made against CIO in such proceedings.

    6.2 If within 120 days after having been notified of any alleged
infringement, CDS (or UKRF) shall have been unsuccessful in obtaining the
agreement of the alleged infringer to desist from the infringing activities, or
shall not have brought and be diligently prosecuting an infringement action, or
if CDS shall have notified CIO of its intention not to bring suit against the
alleged infringer, then (and only then) CIO shall have the right, but not the
obligation, to prosecute such infringement at its own expense with counsel to
which CDS has no reasonable objection. In such case CIO shall have the right to
withhold from its royalty obligations pursuant to Article 3, to the extent of
CIO's expenses then incurred in connection with such suit, 50 % of the royalties
otherwise thereafter due hereunder to CDS and UKRF, and CIO shall apply the
reduced amounts toward reimbursement of CIO's expenses, including reasonable
attorneys' fees, in connection with such suit, until such time as such expenses
shall have been fully reimbursed. If such expenses are less than the maximum
amount that may be credited, the credit shall be applied first against the
royalties due UKRF and then against the royalties due CDS. CIO shall consult
with CDS on material aspects of such litigation. No settlement, consent judgment
or other voluntary final disposition of the suit may be entered into without the
consent of CDS which consent shall not be unreasonably withheld or delayed. CIO
shall indemnify CDS and UKRF against any order for costs that may be made
against either of them in such proceedings.

          Any recovery of damages in any such suit shall be applied first in
satisfaction of any unreimbursed expenses and legal fees of CIO in connection
with the suit, and next toward reimbursement of CDS and UKRF for any royalties

                                       7
<PAGE>

[*]=CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETED ASTERISKS HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

withheld and applied pursuant to this Article 6. The balance remaining from any
such recovery shall be retained by CIO, provided that such remaining balance
shall be deemed included within Net Sales under this Agreement and shall bear
royalties as provided herein.

    6.3 In the event that a declaratory judgment action alleging invalidity or
non-infringement of any of the Licensed Patent Rights shall be brought against
CIO, CDS, at its option, shall have the right, within thirty (30) days after
commencement of such action, to intervene and take over the defense of the
action at its own expense; provided that CDS shall consult with CIO on material
aspects of such litigation and provided further that CDS shall select counsel to
which CIO has no reasonable objection. No settlement, consent judgment or other
voluntary final disposition of the suit may be entered into without the consent
of CDS which consent shall not be unreasonably withheld or delayed.

    6.4 Should CDS or CIO commence a suit under the foregoing provisions and
thereafter elect to abandon the same, the abandoning party shall give timely
written notice to the other party and such other party may continue prosecution
of such suit, with the expenses and recovery being allocated as set forth in
Sections 6.1, 6.2, and 6.3.

          In the event of any infringement suit against a third party brought by
either party pursuant to this Article 6, the party not bringing such suit shall
cooperate in all respects, execute any documents reasonably necessary to permit
the other party to prosecute such suit, and to the extent reasonable shall make
available its employees and relevant records to provide evidence for such suit.

    6.5 If, during the term of this Agreement, any third party (other than an
Affiliate of a party) claims that CIO's making, using or selling of Licensed
Products hereunder infringes on a third-party patent based upon claims that
dominate claims in the Licensed Patent Rights, within 120 days after notice by
CIO, CDS shall either (i) procure for CIO the right to exercise all rights
licensed under this Agreement without any additional payment therefor by CIO, or
(ii) advise CIO that it elects not to procure such rights itself. If CDS does
not procure such right within such 120 day period after notice of such claim by
CIO, CIO shall have the right, but not the obligation, to procure such rights
itself and offset one-half of any royalty payments hereunder on a product-by-
product basis, by the amount paid by CIO for such third-party rights, provided
that the offset under this provision shall not be used to reduce the royalty
payment for any period by more than [*] of Net Sales for CDS and [*] of Net
Sales for UKRF, and any amount remaining to be offset from any period shall be
carried forward until offset against royalties for future periods.

7.  Development of Products
    -----------------------

    7.1 CDS will be responsible for developing and testing, through Phase I
clinical trials, each of the Initial Ophthalmic Products, including but not
limited to preclinical testing, manufacturing or otherwise sourcing product for
preclinical and clinical testing, clinical data gathering, biostatistics
analysis and preparation of pertinent FDA documents to be filed by CIO. Such
development efforts shall be performed substantially in accordance with the R&D
plan and with such protocols and priorities as are mutually agreed upon by CIO
and CDS within 30 days after the date of this Agreement (the "Initial Product
R&D Plan"). CDS shall perform such activities in a timely manner to achieve the
goals of the Initial Product R&D Plan.

                                       8
<PAGE>

        7.1.1 In carrying out the Initial Product R&D Plan, CDS shall consult
regularly with CIO, provide CIO complete disclosure of all material developments
and technical information, and obtain CIO's consent before any substantial
modification of such plan. If the Plan is modified as to any of the Initial
Ophthalmic Products in a manner that would reduce the total amount of any
investment in development of such product, CIO and CDS shall mutually agree on
the reallocation of such funding to one of the other Initial Ophthalmic Products
or to the development of an additional Licensed Product or as otherwise mutually
agreed.

    7.2 CDS and CIO shall collaborate on the planning and implementation of
Phase II and Phase II/III clinical studies involving the Initial Ophthalmics
Products, and shall mutually agree on the protocol for each such study (except
for the ganciclovir clinical study, which is in progress at the date of this
Agreement). Unless mutually agreed otherwise, the outside costs of each Phase II
or II/III study will be co-funded by CDS and CIO consistent with the budget set
forth on Exhibit 7.2. CDS shall produce, analyze and supply products for Phase
II or II/III studies and CIO will provide clinical and regulatory support, each
at its own expense. If CIO notifies CDS of a proposed Phase I, II or II/III
clinical study on an Initial Ophthalmic Product, which study is not included in
the Initial Product R&D Plan, and CDS declines to participate in such study, CIO
shall have the right to manage and fund such study without further participation
of CDS.

    7.3 CIO will be responsible for managing and funding Phase III clinical
studies on the Initial Ophthalmic Products in a reasonable manner. In managing
such studies CIO shall consult with and take under advisement input from CDS.

    7.4 CIO shall use reasonable efforts to keep CDS fully informed of CIO's
plans with respect to development of each Licensed Product under active
development, prior to filing an INDA on such product.

     With respect to Licensed Products other than the Initial Ophthalmics
Products that CIO desires to develop, CIO shall notify CDS of CIO's development
plans for such product and CDS shall have the opportunity to perform in vitro
studies on drug release and design of such product, provided that CDS will
report its results to CIO and maintain such results in confidence as provided
herein and that CDS will not obtain any additional rights in such products by
virtue of performing such studies.

    7.5 CIO shall own all preclinical and clinical data, and any proprietary
interests therein, resulting from the development efforts referred to in this
Article 7, and shall have a right to use and reference any such data, or
background information of CDS related to such preclinical and clinical data, for
the purpose of developing and making, using and selling Licensed Products,
including obtaining regulatory approval to market such products. Notwithstanding
anything to the contrary herein, all applicable regulatory filings on the
Licensed Products (including, but not limited to any INDA or NDA) shall be
performed in the name of and held by CIO, unless determined otherwise in CIO's
sole discretion.

                                       9
<PAGE>

    7.6 CIO shall use reasonable diligence to bring the Initial Ophthalmic
Product containing ganciclovir (the "GVC Product") to market and to evaluate,
develop and commercialize other Licensed Products. CIO agrees that if it does
not file with the FDA its NDA for approval to market GVC Product within two
years after the date of this Agreement., it shall pay $100,000 to CDS within 30
days after notice thereof from CDS, in order to maintain this Agreement in
effect. Such payment shall be an advance payment of royalties fully creditable
against royalties payable under Article 3. If such NDA is not filed within three
years after such date, CIO shall make an additional payment of $100,000 to CDS
(which second payment shall not be creditable against royalties), within 30 days
after notice thereof from CDS, in order to maintain this Agreement in effect. If
either such payment is not made in a timely manner, CDS shall have the right to
terminate this Agreement upon written notice to CIO. In addition, CDS shall have
the right to terminate this Agreement upon written notice to CIO if CIO has not
filed such NDA within four years after the effective date hereof.

    7.7 If CIO reasonably determines that it would not be technically or
commercially feasible to further develop such GVC Product, it shall promptly
meet and confer with CDS and determine an appropriate alternative product to
develop as a first priority. If such an alternative product is selected or if
CIO's development of the GVC Product is delayed due to causes beyond CIO's
reasonable control, CIO and CDS shall negotiate in good faith to adjust the
above milestone dates to accommodate such changes reasonably.

    7.8 During the term of this Agreement CIO shall maintain in effect a sales
force dedicated primarily to servicing the requirements of ophthalmic surgeons
in order to promote and market Licensed Products.

8.  Representations and Warranties
    ------------------------------

    8.1 Each party hereby represents and warrants to the other as follows:
8.1.1  It is a corporation duly organized and validly existing and in good
standing under the laws of its state of incorporation.
8.1.2  It has power and authority to execute and deliver this Agreement, and to
perform its obligations hereunder.

        8.1.3 Except as set forth in Exhibit 8.1.3, the execution, delivery and
performance by it of this Agreement and its compliance with the terms and
provisions hereof does not and will not conflict with or result in a, breach of
any of the terms and provisions of or constitute a default under (i) any loan
agreement, guaranty, financing agreement, agreement affecting any of the
Licensed Patent Rights or other agreement or instrument binding or affecting it
or its property; (ii) the provisions of its charter document or by-laws; or
(iii) any law, rule, regulation or any order, writ, injunction or decree of any
court or governmental authority entered against it or by which any of its
property is bound.

        8.1.4 This Agreement has been duly authorized, executed and delivered by
it and constitutes its legal, valid and binding obligation enforceable against
it in accordance with its terms subject, as to enforcement, to bankruptcy,
insolvency, reorganization and other laws of general applicability relating to
or affecting creditors' rights and to the availability of particular remedies
under general equity principles.

                                       10
<PAGE>

        8.1.5 There are no actions, suits or proceedings pending or, to its
knowledge, threatened against it or its Affiliates which affect its ability to
carry out its obligations under this Agreement.

    8.2 In addition to the foregoing, CDS represents, warrants and covenants to
CIO as follows:

        8.2.1 There are no actions, suits or proceedings pending or, to CDS's
knowledge, threatened against CDS or any of its Affiliates, at law or in equity
before any court or administrative office or agency which affect the Licensed
Patent Rights or the Licensed Products .

        8.2.2 To CDS's knowledge, CIO's practice of the Licensed Patent Rights
as contemplated by this Agreement will not involve any infringement or
constitute an unauthorized use of any patent, copyright, trade secret,
proprietary information, license or right therein belonging to any third party.

        8.2.3 Each of the patent applications included in the Licensed Patent
Rights is currently pending and in good standing, and has not been abandoned.
CDS has no knowledge of any fact or circumstance, other than as set forth in
Exhibit 8.2.3, that could adversely affect CDS ability to obtain patents based
on such applications or the validity of such patents if any are issued.

        8.2.4 CDS has provided CIO with a true and complete copy of the UKRF
License. The UKRF License is in full force and effect, and has not been amended
or modified.

9.  Indemnity
    ---------

    9.1 Each party agrees to indemnify and hold the other party and its
Affiliates, officers, directors, employees, agents and shareholders harmless
against any and all losses, liabilities, damages, claims, judgments, demands,
and expenses (including reasonable attorneys' fees) and costs (together or
individually, a "Loss") arising out of or in connection with (i) the breach by
the indemnifying party of any of its representations or warranties contained in
this . Agreement, (ii) the nonperformance, partial or total, of any covenants of
the indemnifying party contained in this Agreement; or (iii) any alleged act or
omission of CDS in carrying out the development of any Licensed Products prior
to the effective date of this Agreement, including but not limited to clinical
testing of such products.

    9.2 CIO agrees to indemnify and hold CDS and UKRF, and each of their
Affiliates, trustees, officers, directors, employees and shareholders harmless
against any Loss arising out of any death or injury to any person or persons or
out of damage to any property resulting from the production, manufacture, use,
consumption, sale or advertisement of the Licensed Products and Licensed
Processes hereunder by CIO and its Affiliates, except to the extent such Loss
results from negligence or nonperformance of contractual obligations hereunder
by the party to be indemnified.

                                       11
<PAGE>

    9.3 As a condition to the indemnified party's right to indemnification under
this Article, the indemnified party shall give prompt notice to the indemnifying
party of any suits, claims or demands by third parties or the indemnified party
which may give rise to any Loss for which indemnification may be required under
this Section. The indemnifying party shall be entitled to assume the defense and
control of any suit, claim or demand of any third party at its own cost and
expense; provided, however, that (i) the other party shall have the right to be
represented by its own counsel at its own cost in such matters, and (ii) any
settlement of such suit, claim or demand shall be subject to the prior written
consent of such other party, which consent shall not be withheld or delayed
unreasonably.

    9.4 CIO shall promptly obtain and maintain insurance in amounts not less
than $5,000,000 covering liabilities arising out of the manufacture, use and
sale of Licensed Products or Licensed Processes and shall provide CDS and UKRF
evidence of product liability insurance.

10.  Ownership of Proprietary Information; Confidentiality
     -----------------------------------------------------

    10.1 Each party shall own all right, title and interest in and to any
proprietary information which is developed or acquired by such party or its
Affiliates or agents in the course of performing activities under this
Agreement, subject to any license rights granted to the other party under this
Agreement and the provisions of Section 7.5.

    10.2 Each party shall itself, and shall cause its employees and agents to,
use diligent efforts to keep confidential and to refrain from using, except, as
contemplated in this Agreement, all Licensed Know-How and all confidential
business and technical information disclosed to such party by the other party,
during the term of and for a period of three years after the termination of this
Agreement. The foregoing shall not apply to such information that a party can
demonstrate (a) was known to such party before it was disclosed to such party,
(b) was known to the public at the time of disclosure, or subsequently becomes
so known through no act or omission of such party, (c) is received by such party
from a third party not under any obligation of confidentiality, or (d) is
developed by such party independently of any disclosure hereunder. Nothing
contained in this Section shall be deemed to restrict the use of such
confidential business information or Licensed Know-How as necessary and proper
to exercise the parties' rights under this Agreement, or to comply with the
parties' obligations under this Agreement.

    10.3 Prior to public disclosure by either party of the existence of this
Agreement or of any of its terms and conditions, the party proposing to disclose
such information shall provide the other party with advance written notice
thereof and a copy of such proposed disclosure. Such disclosure shall not be
made without the prior written consent to such disclosure by the other party,
which consent shall not be unreasonably withheld or delayed.

11.  CIO Rights of First Negotiation
     -------------------------------

    11.1 CDS hereby grants to CIO during the term of this Agreement a right of
first negotiation to license, on a product-by-product basis, products developed
or to be developed by CDS to the extent they are not licensed under other

                                       12
<PAGE>

provisions of this Agreement. CDS shall notify CIO of each such product
including in such notice information available to CDS that is reasonably
necessary for making a decision to invest in such product (the "Product
Opportunity Notice"). If CIO notifies CDS within 30 days of receipt of a Product
Opportunity Notice that CIO desires to evaluate such product opportunity, CDS
and CIO shall negotiate in good faith during the period ending 120 days after
the date of the Product Opportunity Notice (the "Negotiation Period"), to
participate in the development of and/or to enter into a license to commercially
exploit such product on reasonable commercial terms. During the Negotiation
Period, CDS shall supply CIO on a confidential basis with additional information
reasonably requested by CIO and available to CDS, and cooperate (at CIO's
expense) in any experiments reasonably requested by CIO designed to evaluate the
product opportunity. If CIO and CDS cannot reach agreement on such a license
during the Negotiation Period, then (i) CDS may contact third parties regarding
a potential license for such product, provided CDS takes appropriate steps to
protect the confidentiality of CDS's proprietary information, and does not
reveal any CIO proprietary information; and (ii) CDS may license its rights in
the product to a third party, but only on terms more favorable overall to CDS
than the terms offered to CIO. If CDS does not enter into such a third-party
license relating to such product within one year after the beginning of a
Negotiation Period, then CDS shall re-submit to CIO a new Product Opportunity
Notice regarding such product, and again follow the foregoing procedures before
licensing such product to a third party. If CIO or its assignee does. not give a
CIO Notice within the 30-day period, CDS may license such product to third
parties in its discretion. Nothing herein shall be deemed to obligate CIO to
grant any CIO technology rights (including its rights in the Licensed Patent
Rights) to CDS or a third party as a result of a product license by CDS under
this Section.  CIO shall have the right to assign its rights to negotiate and
obtain any license hereunder to an Affiliate of CIO after CIO receives the
Product Opportunity Notice relating to such opportunity.

12.  Required Consents; Subsequent Events
     ------------------------------------

    12.1 Anything in this Agreement to the contrary notwithstanding, this
Agreement shall not constitute a license or sublicense of any Licensed Patent
Rights or Licensed Know-How if an attempted license thereof would constitute a
breach of any enforceable agreement or would be ineffective, in either case
without the consent or waiver of a third party to such license, or would violate
any applicable law; provided, however, that this provision shall not be deemed
to modify in any respect any of CDS's representations or warranties.

    12.2 CDS shall use reasonable efforts to obtain all such consents and
waivers. Until such consent or waiver has been obtained, CIO shall use
reasonable efforts to perform in CDS's name and, in respect of the incremental
costs incurred by CIO in performing in CDS's name, at CDS's expense, all of
CDS's obligations with respect to each item of Licensed Patent Rights or
Licensed Know-How for which any such consent or waiver has not been obtained.

    12.3 If any such item of Licensed Patent Rights or Licensed Know-How is not
licensed to CIO pursuant to this Article 12, CDS shall cooperate with CIO in any
reasonable arrangement designed to provide for CIO all of the benefits of, and
to have CIO assume the obligations and expenses expressly assumed by CIO
hereunder with respect to, all such licensed intellectual property. At CIO's
request, CDS shall take all reasonable actions requested by CIO to enforce for
the benefit of CIO any and all rights of CDS with respect to any such licensed
intellectual property that is not otherwise licensed pursuant to the provisions
of this Agreement.  Nothing herein shall create or provide any rights or
benefits in or to third parties.

                                       13
<PAGE>

    12.4 If a claim brought by any party challenging any of the transactions
contemplated hereby results in any ruling or order which has the result of
frustrating in a material way the licensing of the intellectual property
licensed hereunder to CIO or use thereof pursuant to the applicable CIO
licensing provisions contained herein, CDS shall cooperate with CIO in any
reasonable arrangement designed to give CIO, a nearly as possible, the same
economic benefits, and to have CIO assume the same obligations and expenses, as
if such license had been consummated in accordance with the provisions hereof.

    12.5 Upon the occurrence of any of the events specified in Section 12.3
and/or Section 12.4, CIO and CDS agree to attempt for sixty (60) days to reach
agreement on the manner in which the provisions of those sections shall be
implemented. If, at the end of such sixty (60) day period, such negotiations
have not resulted in an agreement, then either. CIO or CDS may elect, by written
notice to the other, to have the matter finally settled by an arbitration to
take place in accordance with the rules of the American Arbitration Association
(the "AAA"). There shall be one arbitrator selected by mutual agreement of CDS
and CIO or if they are unable to agree by the AAA. The arbitrator shall hear
evidence and shall have the power to order production of such documents from CIO
and CDS as the arbitrator shall determine necessary.

13.  Term; Termination
     -----------------

    13.1 This Agreement shall become effective as of the date hereof and shall
continue until the expiration of all Licensed Patent Rights, unless earlier
terminated in accordance with Section 13.2 or unless extended or terminated by
mutual written agreement of the parties.  Upon  expiration of all Licensed
Patent Rights if this Agreement has not been earlier terminated, CIO shall have
a fully paid-up license under the rights granted in Article 2, subject to
payment of all royalties and provision of all reports pursuant to Section 13.3.

    13.2 This Agreement may be terminated (i) by either party upon the material
breach of this Agreement by the other party if such breach is not cured within
60 days after written notice from the nonbreaching party; provided, however,
that termination of this Agreement is not intended to be the sole remedy of
either party in the event of a breach of this Agreement by the other party, and
in the event of a breach of this Agreement by one party, the other party shall
be entitled, in addition, to all remedies available at law or in equity; and
provided, further, that if the material breach is a nonpayment of amounts due
hereunder, such cure period shall be 30 days after such written notice, or (ii)
by either party upon the bankruptcy, insolvency, assignment for the benefit of
creditors or other act of insolvency by, of or against the other party or its
parent, if any; or (iii) by CIO, at its option, upon 180 days' written notice to
CDS; or (iv) by CDS pursuant to Section 7.6.

    13.3 Termination of this Agreement shall be without prejudice to (i) CDS's
rights to receive royalty payments accrued hereunder and related reports; (ii)
each party's rights and obligations under Articles 9, 10 and 14 or (iii) any
other rights or remedies available to the parties. Upon termination CIO shall
have the right, subject to payment of the royalties and provision of related
reports as herein provided, to continue to sell Licensed Products in its
inventory at the time of termination, but in no event for more than one year
after termination.

                                       14
<PAGE>

[*]=CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETED ASTERISKS HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

    13.4 Notwithstanding anything to the contrary in this Agreement (including
but not limited to Section 14.1), CIO shall have the right, upon 180 days'
notice to CDS, to terminate the license hereunder with respect only to Licensed
Patent Rights sublicensed from UKRF, and not with respect to other rights
licensed hereunder. (Such a termination shall be referred to herein as a "Patent
Rights Termination".) Upon receipt of notice from CIO of a Patent Rights
Termination, CDS shall notify UKRF of such termination and either terminate the
UKRF License as of the same date as the Patent Rights Termination or make such
other arrangements for fulfilling CDS's obligations under the UKRF License as
CDS deems appropriate. As of the effective date of a Patent Rights Termination,
(i) CIO's obligations and rights as sublicensee under the UKRF License shall
terminate, including but not limited to CIO's obligation to pay royalties for
UKRF under Section 3.3; (ii) CIO's royalty payments under Section 3.2 for the
GVC Product shall be further reduced to [*] of Net Sales of such product after
[*} in aggregate Net Sales for such product have been achieved; and (iii) CIO's
royalty payments under Section 3.2 for all other Licensed Products shall be
reduced to a flat [*] of Net Sales regardless of the level of Net Sales. Upon a
Patent Rights Termination, the term "Licensed Product" hereunder shall be deemed
to mean a sustained-release drug delivery system for use in Ophthalmic
Applications, the manufacture, use or sale of which utilizes Know-How owned or
controlled by CDS.

14.  Miscellaneous
     -------------

    14.1 To the extent this Agreement includes a sublicense of rights licensed
under the UKRF License, CIO acknowledges and agrees that the terms of such
sublicense shall be subject to the terms and conditions of the UKRF License, a
copy of which is attached hereto as Exhibit 14.1. To the extent the terms and
conditions of the UKRF License are inconsistent with the terms of this
Agreement, with respect to the rights sublicensed from UKRF the terms of the
UKRF License shall prevail; provided, however, that CDS shall use its best
efforts to obtain the agreement of UKRF to obtain the agreement of UKRF to amend
the UKRF License to the extent necessary to make such license consistent with
the terms of this Agreement, and if CDS is not successful in obtaining such
amendments the terms and conditions of Sections 3.4 and 6.5 of this Agreement
shall be modified to provide to CIO substantially the same economic benefits and
burdens as if such amendment had been obtained and Section 6.1 shall be modified
to provide that, if CDS recovers any damages from a third party infringer above
the amount necessary to reimburse its costs of suit, CDS will pay to CIO one-
half of any such amount that CDS is entitled to retain under the UKRF License.

    14.2 This Agreement may be executed in any number of counterparts, each of
which when so executed shall be deemed to be an original and all of which taken
together shall constitute this Agreement.

    14.3 Any notice or other communication required or permitted to be given by
either party under this Agreement shall be given in writing and shall by
effective when delivered, if delivered by hand or by electronic facsimile or
five days after mailing if mailed by registered or certified mail, postage
prepaid and return, receipt requested, addressed to each party at the following
addresses or such other address as may be designated by notice pursuant to this
Section 14.3:

                                       15
<PAGE>

     If to CDS:   Control Delivery Systems, Inc.
                  2702 Whitney Avenue Hamden, CT 06518
     Attn:        Mr. Vincent Manopoli:
     Facsimile:   (203) 288-7687

     If to CIO:   Chiron IntraOptics
                  9342 Jeronimo Road
                  Irvine, CA 92718
     Attn:        Dr. William J. Link
     Facsimile:   (714) 768-4882

    14.4 If any provision of this Agreement is held to be invalid, void or
unenforceable for any reason, it shall be adjusted, if possible, rather than
voided in order to achieve the intent of  the parties to the maximum extent
possible. In any event, all other provisions of this Agreement shall be deemed
valid and enforceable to the fullest extent possible.

    14.5 No amendment, modification or addition hereto shall be effective or
binding on either party unless set forth in writing and executed by a duly
authorized representative of the party to be charged.

    14.6 No waiver of any rights under this Agreement shall. be deemed effective
unless contained in a writing signed by the party charged with such waiver, and
no waiver of any breach or failure to perform shall be deemed to be a waiver of
any future breach or failure to perform or any other right arising under this
Agreement.

    14.7 The section headings contained in this Agreement are included for
convenience only and form no part of this Agreement between the parties.

    14.8 This Agreement shall not be assignable by any party hereto, whether by
assignment, merger, sale of assets or otherwise, without the prior written
consent of the other party, which consent shall not be unreasonably withheld;
provided, however, that no consent shall be required for any assignment of this
Agreement by CIO to an Affiliate of CIO.  Any purported assignment in
contravention of this Section 14.8 shall, at the option of the nonassigning
party, be null and void and of no effect.  Except as otherwise provided above,
this Agreement shall be binding upon and inure to the benefit of the successors
and assigns of the parties.

    14.9 All provisions of this Agreement which, by their terms, require
performance after the termination of the Agreement shall survive the termination
of this Agreement.

    14.10 Except as otherwise provided herein, each party shall bear its own
legal fees incurred in connection with the transactions contemplated hereby,
provided, however, that if any party to this Agreement seeks to enforce its
rights under this Agreement by legal proceedings or otherwise, the non-
prevailing party shall pay all costs and expenses incurred by the prevailing
party, including, without limitation, all reasonable attorneys' fees.

                                       16
<PAGE>

    14.11 Neither party shall use the name, tradename or trademark of the other
party in connection with this Agreement without the express prior written
consent of the other party, and nothing herein shall be deemed to require any
party to use any name or mark of the other party in connection with
commercialization of products hereunder.

    14.12 This Agreement (together with the exhibits and schedules hereto as
such exhibits may be amended from time to time in accordance with this
Agreement), constitutes the entire Agreement between the parties with respect to
the subject matter hereof and thereof. All prior or contemporaneous agreements,
whether written or oral, and all proposals, understandings and communications
between or involving the parties hereto are hereby canceled and superseded.

                                       17
<PAGE>

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
which appears in the first paragraph of this Agreement.

CDS:      CONTROL DELIVERY SYSTEMS, INC.

          By: /s/ Vincent C. Manopoli
              ------------------------------
          Title: President
                ---------------------------

CIO:      CHIRON INTRAOPTICS, INC.

          By: /s/ William Link
              -----------------------------
          Title: Chairman and CEO
                --------------------------

                                       18
<PAGE>

             AMENDMENT NO. 1 TO LICENSE AND DEVELOPMENT AGREEMENT
             -----------------------------------------------------

     This Amendment No. 1 (the "Amendment") to the License and Development
Agreement (the "License Agreement") dated as of December 31, 1992 by and between
Control Delivery Systems, Inc., a Delaware corporation ("CDS") and Chiron
IntraOptics, Inc., a Delaware corporation ("CIO") is made as of August 16, 1993.

                                   Background
                                   ----------

     The parties wish to clarify a provision to the License Agreement.

NOW, THEREFORE, CDS and CIO agree as follows:

     1.  The last sentence of Section 13.4 of the License Agreement shall be
amended to read in its entirety as follows:

     Upon a Patent Rights Termination, the term "Licensed Product" hereunder
     shall be deemed to mean a sustained-release drug delivery system for use in
     Ophthalmic Applications, the manufacture, use or sale of which utilizes
     Licensed Know-how owned or controlled by CDS, and the term "Licensed Know-
     How" shall be deemed to mean any and all Know-How owned and controlled by
     CDS which is necessary or useful for making, using or selling a sustained-
     release drug delivery system for use in Ophthalmic Applications, including
     but not limited to in vitro, preclinical and clinical data, regulatory
     filings, and manufacturing information. CDS warrants and represents, and
     CIO acknowledges, that CDS has significant Know-How which CDS will provide
     to CIO pursuant to this Agreement.

     2.  The License Agreement is in all other respects confirmed.

     IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
which appears in the first paragraph of this Amendment.

                              CDS: Control Delivery Systems, Inc.

                              By: /s/ Vincent C. Manopoli
                                 ---------------------------------
                                  President

                              CIO: Chiron IntraOptics, Inc.

                              By: /s/ William Link
                                 ---------------------------------
                                  President

                                      19
<PAGE>

              AMENDMENT NO. 2 TO LICENSE AND DEVELOPMENT AGREEMENT
              ----------------------------------------------------

     This Amendment No. 2 (the "Amendment") to the License and Development
Agreement (the "License Agreement") dated as of December 31, 1992, by and
between Control Delivery Systems, Inc., a Delaware corporation, ("CDS") and
Chiron Vision Corporation (formerly Chiron IntraOptics, Inc.), a Delaware
corporation, ("Chiron") as amended August 16, 1993, is made as of this 30th day
of March, 1995.

                                   BACKGROUND
                                   ----------

     A.  The parties desire to amend to the License Agreement as follows:

     NOW, THEREFORE, CDS and Chiron agree as follows:

     1.  All capitalized terms not defined herein shall have the meaning set
forth in the License Agreement.

     2.  The following shall be added to Section 2.2 of the License Agreement:

     CDS shall immediately notify Chiron of (i) any notice from UKRF, whether
written or oral, that CDS is in breach of the UKRF License or that UKRF intends,
or has any basis, to restrict or terminate the UKRF License, or (ii) any
circumstances which would give UKRF the right to do any of the foregoing. In
such event, and in all other circumstances, CDS shall use its best efforts to
maintain the UKRF License. Notwithstanding the foregoing, Chiron shall have the
right to undertake any obligation of CDS under the UKRF License, or to cure any
breach by CDS of the UKRF License, in order to maintain the UKRF License in full
force and effect.  Any expenses incurred by Chiron in so maintaining the UKRF
License shall, at Chiron's election, be promptly reimbursed by CDS to Chiron or
subject to offset by Chiron of any amount due CDS hereunder.

     3.  The following shall be added as Section 3.6 of the License Agreement:

          3.6  In addition to the initial license fee set forth in Section 3.1,
     on or before March 31, 1995, Chiron shall pay CDS two hundred and fifty
     thousand dollars, ($250,000), which shall be fully creditable against any
     earned royalties that become payable hereunder with respect to Net Sales of
     Licensed Products after January 1, 1997. Such credit shall be taken by
     Chiron against fifty percent of royalties otherwise actually payable in
     cash (i.e. after the use of the credit arising from the initial license fee
     set forth in Section 3.1, or any other credits or offsets) with respect to
     Net Sales after such date, so that of the first five hundred thousand
     dollars ($500,000) of royalties (after giving effect to such credits or
     offsets), CDS shall receive two hundred and fifty thousand dollars
     ($250,000).

     4.  Section 6.1, 6.2 and 6.3 of the License Agreement are amended in their
entirety to read as follows:

                                      20
<PAGE>

          6.1  CDS shall inform Chiron promptly of any alleged infringement
     involving Ophthalmic Applications by third parties of any Licensed Patent
     Rights and provide any information available to CDS relating to such
     alleged infringement. Chiron shall have the right, but not the obligation,
     to prosecute such infringement at its own expense with counsel to which CDS
     has no reasonable objection. Chiron shall consult with CDS on material
     aspects of such litigation. No settlement, consent, judgment or other
     voluntary final disposition of the suit may be entered into without the
     consent of CDS which consent shall not be unreasonably withheld or delayed.
     Chiron shall indemnify CDS and UKRF against any order for costs that may be
     made against either of them in such proceedings.

     Any recovery of damages in any such suit shall be applied first in
     satisfaction of any expenses and legal fees incurred by Chiron to third
     parties in connection with the suit. Thirty percent (30%) of the balance
     remaining from any such recovery shall be retained by Chiron and seventy
     percent (70%) of such balance shall be retained by CDS.

          6.2  If within 120 days after having been notified of any alleged
     infringement, Chiron shall have been unsuccessful in obtaining the
     agreement of the alleged infringer to desist from the infringing
     activities, or shall not have brought and be diligently prosecuting an
     infringement action, or if Chiron shall have notified CDS of its intention
     not to bring suit against the alleged infringer, then (and only then) CDS
     shall have the right, but not the obligation, to prosecute such
     infringement at its own expense with counsel to which Chiron has no
     reasonable objection. In such event, unless otherwise agreed by CDS and
     Chiron, CDS shall bear the costs of any such infringement suit commenced by
     CDS and shall keep any recovery derived therefrom. CDS shall consult with
     Chiron the material aspects of such litigation, and shall select counsel to
     which Chiron has no reasonable objection. No settlement, consent judgement
     or other voluntary final disposition of the suit may be entered into
     without the consent of Chiron, which consent shall not be unreasonably
     withheld or delayed. CDS shall indemnify Chiron against any order for costs
     that may be made against Chiron in such proceedings.

          6.3  In the event that a declaratory judgment action alleging
     invalidity or non-infringement of any of the Licensed Patent Rights shall
     be brought against Chiron, and in such event Chiron does not elect to
     defend against such action, CDS, at its option, shall have the right,
     within thirty (30) days after commencement of such action, to intervene and
     take over the defense of the action at its own expense; provided that CDS
     shall consult with Chiron on material aspects of such litigation and
     provided further that CDS shall select counsel to which Chiron has no
     reasonable objection.  No settlement, consent judgement or other voluntary
     final disposition of the suit may be entered into without the consent of
     CDS which consent shall not be unreasonably withheld or delayed.

                                      21
<PAGE>

     5.  Section 9.1 of the License Agreement is amended to add the following
sentence:

     "For purposes hereof, a Loss' of Chiron shall include any amounts paid by
     Chiron to a third party pursuant to any agreement between Chiron and the
     third party for the manufacture, distribution, promotion or sale of the
     Licensed Products."

     6.  Section 10.2 of the License Agreement is amended to add the following
sentence:

     "Notwithstanding the foregoing, Chiron may disclose such confidential
     business and technical information received by it from CDS to any third
     party that has entered an agreement with Chiron for the manufacture,
     distribution, promotion or sale of the Licensed Products so long as such
     third party is bound by confidentiality provisions substantially equivalent
     hereto."

     7.  The License Agreement is in all other respects confirmed.

     IN WITNESS WHEREOF, the parties have executed this Amendment as of the date
which appears in the first paragraph of this Amendment.

                                        Control Delivery Systems, Inc. ("CDS")

                                        By: /s/ Paul Ashton
                                           -----------------------------

                                        Its: President
                                            ----------------------------

                                        Chiron vision Corporation ("Chiron")

                                        By: /s/ William Link
                                           -----------------------------
                                             President

                                      22
<PAGE>

                                  SEP - 7 1995

CONTROL
DELIVERY
SYSTEMS INC.

August 21, 1995

William Link, Ph.D.
Chiron Vision Corporation
500 Iolab Drive
Claremont, CA 91711

Dear Bill:

Reference is made to a certain License and Development Agreement (the "License
Agreement"), dated as of December 31, 1992, by and between Control Delivery
Systems, Inc. ("CDS") and Chiron Vision Corporation (formerly Chiron
Intra0ptics, Inc.) ("Chiron"), as amended by Amendment No. 1 to License and
Development Agreement, dated as of August 16, 1993, as further amended by
Amendment No. 2 to License and Development Agreement, dated as of March 30,
1995, as further amended by Amendment No. 3 to License and Development
Agreement, dated as of June 23, 1995 ("Amendment No. 3").

CDS agrees that if Development Product No. 1 (as the term is defined in
Amendment No. 3) falls outside of the scope of the Licensed Patents (as that
term is defined in the License Agreement), CDS and Chiron shall enter into a
license agreement on substantially similar terms as the license agreement
concerning Development Product No. 1.

Very truly yours,

/s/ Vincent Manopoli

Vince Manopoli
Chief Operating Officer

Accepted By: /s/ William Link
            --------------------------------
Name: William Link
     ---------------------------------------
Title: Chairman and CEO
      --------------------------------------

Telephone: (407) 395-6922 . 2424 N. Federal Highway, Suite 362, Boca Raton, FL
33431 . Fax: (407) 395-7426

                                      23
<PAGE>

              Amendment No. 3 to License and Development Agreement
              ----------------------------------------------------

     This Amendment No. 3 (the "Amendment") is made and entered into as of
June 23, 1995 and amends the License and Development Agreement (the "License
Agreement"), dated as of December 31, 1992, by and between Control Delivery
Systems, Inc., a Delaware corporation ("CDS"), and Chiron Vision Corporation, a
Delaware corporation ("CIO"; formerly Chiron IntraOptics, Inc.), as amended by
Amendment No. 1 to License and Development Agreement, dated as of August 16,
1993, and as further amended by Amendment No. 2 to License and Development
Agreement, dated as of March 30, 1995.

     NOW, THEREFORE, in consideration of the mutual agreements provided herein,
CDS and CIO agree as follows:

I. Amendments to Definitions.
   -------------------------

     Section 1 of the License Agreement is amended to add the following
definition:

     "Development Product No. 1" shall mean a device for intravitreal
     implantation designed to deliver ganciclovir that meets the specifications
     set forth in Exhibit A.

     The definition of Licensed Product in Section 1 of the License Agreement is
amended to add the following to the end of the definition:

     ", including but not limited to the Development Product No. 1."

II. New Section. The License Agreement is amended to add the following new
    -----------
section:

     15. Development Product No. 1
         -------------------------

          15.1 Payments. On June 23, 1995, CIO shall pay to CDS Two Hundred
     Thousand Dollars ($200,000). Upon delivery of a prototype design of the
     Development Product No. 1 to CIO, CIO shall pay to CDS One Hundred Ten
     Thousand Seventy Three Dollars ($110,073). Upon production of clinical
     supplies of Development Product No. 1 to be used for an INDA trial, CIO
     shall pay to CDS One Hundred Ten Thousand Seventy Three Dollars ($110,073).
     Upon the commencement of a Phase I clinical trial concerning the
     Development Product No. 1, CIO shall pay to CDS One Hundred Dollars
     ($100,000). CIO shall make the above payments within thirty days following
     the occurrence of corresponding event, except that CIO shall make the first
     payment above on the indicated date.
<PAGE>

     IN WITNESS WHEREOF, the parties have executed this Amendment as of the day
and year first above written.

CONTROL DELIVERY                  CHIRON VISION CORPORATION
SYSTEMS, INC.

By: /s/ Vincent C. Manopoli        By: /s/ E. Cummings
   -----------------------------      ---------------------------
Name: Vincent C. Manopoli          Name: E. Cummings
     ---------------------------        -------------------------
Title: Chief Operating Officer     Title: Chief Financial Officer
      --------------------------         ------------------------
<PAGE>

                                   Exhibit A

                                 Specifications
                                 --------------

1.  The Development Product No. 1 shall conform to the existing University of
Kentucky patent.

2.  The overall exterior dimensions shall be reduced to allow for implantation
through an incision 4mm or smaller.

3.  The Development Product shall release at the same rate as specified for the
current implant.  Because of increased drug loading it will release for a
minimum of 18 months.
<PAGE>

June 10, 1996

Paul Ashton, Ph.D.
President and Research Director
Control Delivery Systems, Inc.
86 Rosedale Road
Watertown, MA 02172

Dear Paul:

Control Delivery Systems, Inc. ("CDS") and Chiron Vision Corporation ("Chiron")
are parties to that certain License and Development Agreement dated as of
December 31, 1992, as amended by Amendment No. 1 to License and Development
Agreement, dated as of August 16, 1993, as further amended by Amendment No. 2 to
License and Development Agreement, dated as of March 30, 1995, as further
amended by Amendment No. 3 to License and Development Agreement, dated as of
June 23, 1995 (the "Agreement").

Chiron agrees to pay to CDS Sixty Thousand Dollars ($60,000) per mont during
calendar year 1996, beginning June 1, 1996 and ending June 30, 1997 as a payment
against royalties due and owing under the Agreement. Such payments shall be
immediately credited in full against royalties due and owing under the
Agreement without any proration. This letter agreement shall be considered an
amendment to the Agreement. As amended hereby, the Agreement shall continue in
full force and effect.

If you agree with the above, please indicate your agreement by signing where
indicated below.

Very truly yours,

/s/ William J. Link

William J. Link

Agreed to and accepted by Control Delivery Systems.

By: /s/ Paul Ashton
    --------------------

Its: President
    --------------------

Date: 28 June 96
    --------------------

<PAGE>

              AMENDMENT NO. 4 TO LICENSE AND DEVELOPMENT AGREEMENT
              ----------------------------------------------------

     This Amendment No. 4 to the License and Development Agreement (the "License
Agreement") dated December 31, 1992 by and between Control Delivery Systems,
Inc. a Delaware Corporation ("CDS") and Chiron Vision Corporation (formerly
ChironIntraoptics, Inc.) a Delaware corporation ("Chiron") as amended by
Amendment No. 1 to the License and Development Agreement, dated as of August 16,
1993, as further amended by Amendment No. 2 to License and Development
Agreement, dated as of March 30, 1995, as further amended by Amendment No. 3 to
License and Development Agreement, dated as of June 23, 1995, is made s of this
31st day of December 1997.

                                   BACKGROUND
                                   ----------

A.  the parties desire to amend the License Agreement as follows:

NOW, THEREFORE, CDS and Chiron agree as follows:

1.   All capitalized terms not defined herein shall have the meaning set forth
     in the License Agreement.

2.   Section 11 and 11.1 of the License Agreement are amended in their entirety
     to read as follows:

11.  CIO rights of First Negotiation
     -------------------------------

     11.1  CDS hereby grants to CIO during the term of this Agreement a right of
     first negotiation to license, on a product-by-product basis, ophthalmic
     products developed or to be developed by CDS to the extent they are not
     licensed under other provisions of this Agreement CDS shall notify CIO of
     each such product including in such notice information available to CDS
     that is reasonably necessary for making a decision to invest in such
     product (the "Product Opportunity Notice").  If CIO notifies CDS within 30
     days of receipt of a Product Opportunity Notice that CIO desires to
     evaluate such a product opportunity, CDS and CIO shall negotiate in good
     faith during the period ending 120 days after the date of the Product
     Opportunity Notice (the "Negotiation Period"), to participate in the
     development of and/or to enter into a license to commercially exploit such
     product on reasonable commercial terms.  During the Negotiation Period, CDS
     shall supply CIO on a confidential basis with additional information
     reasonably requested by CIO and available to CDS, and cooperate (at CIO's
     expense) in any experiments reasonably requested by CIO designed to
     evaluate the product opportunity.  If CIO and CDS cannot reach agreement on
     such a license during the Negotiation Period, then (i) CDS may contact
     third parties regarding a potential license for such product, provided CDS
     takes appropriate steps to protect the confidentiality of CDS's proprietary
     information, and does not reveal any CIO proprietary information; and (ii)
     CDS may license its rights in the product to a third party, but only on
     terms more favorable overall to CDS than the terms offered to CIO.  If CDS
     does not enter into such an third-party license relating to such product
     within one year after the beginning of a Negotiation Period, then CDS shall
     re-submit to CIO a new Product Opportunity Notice regarding such product,
     and again follow the forgoing procedures before licensing such product to a
     third party.  If CIO or its assignee does not give CDS notice within the

                                       28
<PAGE>

     30-day period, CDS may license such product to third parties in its
     discretion.  Nothing herein shall be deemed to obligate CIO to grant any
     CIO technology rights (including its rights in the Licensed Patent Rights)
     to CDS or a third party as a result of a product license by CDS under this
     Section.  CIO shall have the right to assign its rights to negotiate and
     obtain any license hereunder to an Affiliate of CIO after CIO receives the
     Product Opportunity Notice relating to such opportunity.

     11.2  CDS hereby grants to CIO during the term of this Agreement a right of
     first negotiation to license, on a product-by-product basis, non-ophthalmic
     products developed or to be developed by CDS to the extent they are not
     licensed under other provisions of this Agreement.  CDS shall notify CIO of
     each such product including in such notice information available to CDS
     that is reasonably necessary for making a decision to invest in such
     product (the "Product Opportunity Notice").  If CIO notifies CDS within 30
     days of receipt of a Product Opportunity Notice that CIO desires to
     evaluate such a product opportunity, CDS and CIO shall negotiate in good
     faith during the period ending 90 days after the date of the Product
     Opportunity Notice (the "Negotiation Period"), to participate in the
     development of and/or to enter into a license to commercially exploit such
     product on reasonable commercial terms.  During the Negotiation Period, CDS
     shall supply CIO on a confidential basis with additional information
     reasonably requested by CIO and available to CDS, and cooperate (at CIO's
     expense) in any experiments reasonably requested by CIO designed to
     evaluate the product opportunity.  If CIO and CDS cannot reach agreement on
     such a license during the Negotiation Period, then CDS may contact third
     parties regarding a potential license for such product, provided CDS takes
     appropriate steps to protect the confidentiality of CDS's proprietary
     information, and does not reveal any CIO proprietary information.  If CIO
     or its assignee does not give CDS within the 30-day period, CDS may license
     such product to third parties in its discretion.  Nothing herein shall be
     deemed to obligate CIO to grant any CIO technology rights (including it
     rights in the Licensed Patent Rights) to CDS or a third party as a result
     of a product license by CDS under this Section.  CIO shall have the right
     to assign its rights to negotiate and obtain any license hereunder to an
     Affiliate of CIO after CIO receives the Product Opportunity Notice relating
     to such opportunity.

     IN WITNESS WHEREOF, the parties have executed the Amendment as of the date
     which appears in the first paragraph of this Amendment.

                                        Control Delivery Systems Inc. ("CDS")

                                        By: /s/ Paul Ashton
                                           ----------------------------------
                                            Paul Ashton, President and CEO

                                        Chiron Vision Corporation ("Chiron")

                                        By: /s/ illegible
                                           -----------------------------------

                                       29

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]